Commentary

Morning Consult: Opinion: A Civic Duty to Address Drug Costs

< 1 min
October 02, 2018

BY SHELLEY LYFORD

October 2, 2018

A recent series of events tells us a lot about the state of healthcare in America today: Major nonprofit organizations, business leaders and former top federal officials are all stepping up to confront our broken healthcare system that costs too much, fails us and is unavailable to many. It is not a coincidence bold actions are happening now; we face a yawning gap of healthcare leadership in Washington and a failure of the Trump Administration to keep its promises.

Last month, a coalition of seven American hospital systems and three national foundations, alarmed by rising prices and shortages of critical generic drugs, launched a not-for-profit generic drug companyCivica Rx, to push back and take some control over the pharmaceutical supply. In hopes of increasing competition and lowering prices, the company will focus on establishing price transparency and stable supplies for 14 generic drugs. As a nonprofit, the company will not be beholden to dividends or stock prices. And unlike any pharma company I’m aware of, its CEO is working without pay.

PLEASE READ THE FULL ARTICLE IN MORNING CONSULT

Shelley Lyford is a board member of Civica Rx and president and chief executive officer of the San Diego-based Gary and Mary West Foundation, a nonprofit, nonpartisan organization dedicated to lowering healthcare costs and enabling successful aging for our nation’s seniors.

 
Shelley Lyford
CEO, Chair & Trustee, Gary and Mary West Foundation
CEO & Chair, West Health Institute